drugset
drugset / Trial / NCT04882735

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

NCT04882735 ↗

Phase 3 Withdrawn Eidos Therapeutics, a BridgeBio company
NaSingle-groupOpen-labelTreatment

Summary

Phase 3 efficacy and safety of acoramidis in subjects with symptomatic Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Timeline

Start
2021-09-08
Primary completion
2026-09
Completion
2026-10

Outcome

Outcome not reported

Stopped: “Sponsor's decision to cancel study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoramidis Unknown 800 mg Oral

Indications

familial amyloid neuropathy